Episode 1: Introduction/MDMA Therapy for PTSD

Introducing the Neural Pharm Podcast, featuring your hosts Colby Burns, PharmD, and Christopher Toney, PharmD. Episode 1 establishes the mission of the podcast, and covers the groundbreaking MAPP1 and MAPP2 trials that established MDMA as a breakthrough therapy for PTSD. We also cover key safety data including drug interactions, pharmacokinetics (or metabolism), and pharmacogenomics (or gene-drug interactions). Come join us! ***Correction Alert: The Ted talk referenced by Colby in the conclusion of the podcast was given by Dr. Ben Sessa, not Sassa (see the attached video in the reference section)**** References: * Mitchell J, et al. MDMA Assisted Therapy for Severe PTSD: A randomized, double blind, placebo controlled phase 3 study. Nature. 10 May 2021 https://www.nature.com/articles/s41591-021-01336-3> * Mental Health By the Numbers. National Alliance on Mental Illness. 2023. * Sessa B, et al. A Review of 3,4-methylenedioxymethamphetamine (MDMA) Assisted Psychotherapy. 2019(10). * Sessa B. Is MDMA psychiatry’s antibiotic? Tedx University of Bristol. 5 July 2016. See video below. * Silverstone P. The Promise of Psychedelics: Science Based Hope for Better Mental Health. 2022 Apr 21. Ingenium books. Referenced in podcast to be discussed in future episode: Christie D, Kryskow P. MDMA Assisted Psychotherapy for Fibromyalgia and Other Centralization Syndromes. Psychedelics Today (podcast). 21 Feb 2023 Get full access to Neural Pharm at neuralpharm.substack.com/subscribe